Published by Clinical Transplantation | The value of dd-cfDNA in evaluating acute rejection treatment

Recently, important research results jointly conducted by Professor Wang Rending’s team at the Kidney Disease Center of the First Affiliated Hospital of Zhejiang University and AlloDx Medical Department were published online in Clinical Transplantation, an authoritative international magazine in the field of organ transplantation. This article reveals the evaluation role of donor-derived cell-free DNA (dd-cfDNA) in the treatment of acute rejection.

This study enrolled 28 patients with acute rejection, including 5 cases of ABMR, 12 cases of type IA or IB TCMR, and 11 cases of type IIA or IIB TCMR. The changes in blood dd-cfDNA content before and after rejection treatment were detected. The results showed that the dd-cfDNA content in the patient's blood dropped from 2.566±0.549% to 0.773±0.116% (P < 0.001). There was a positive correlation between changes in Δdd‐cfDNA% and estimated glomerular filtration rate at 1, 3, and 6 months after treatment (crp = 2.570, P = 0.022). This shows that dd-cfDNA can be used to detect rejection and evaluate the therapeutic effect. In addition, the use of methylprednisolone affects the content of dd-cfDNA.

As a novel biomarker for non-invasive diagnosis of organ transplant rejection, dd-cfDNA has been relatively widely used in clinical practice abroad, but its role in dynamically assessing rejection treatment efficacy has not been reported. According to published literature, this study systematically elucidated the value of dd-cfDNA in rejection treatment, further consolidating the theoretical basis for dd-cfDNA application in organ transplantation. Clinical Transplantation is an authoritative journal in the organ transplantation field with a 33-year history, dedicated to providing cutting-edge and authoritative research progress for physicians and researchers in transplantation.

Original article:https://pubmed.ncbi.nlm.nih.gov/32735352/